Relmada Therapeutics, Inc. RLMD Net investment gains (losses)
Net investment gains (losses) at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RealizedInvestmentGainsLosses.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s net investment gains (losses).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s net investment gains (losses)?
- Relmada Therapeutics, Inc. (RLMD) reported net investment gains (losses) of -$9.87K in Q1 2026.
- How has Relmada Therapeutics, Inc.'s net investment gains (losses) changed year-over-year?
- Relmada Therapeutics, Inc.'s net investment gains (losses) decreased by 115.7% year-over-year, from $62.95K to -$9.87K.
- What is the long-term trend for Relmada Therapeutics, Inc.'s net investment gains (losses)?
- Over 4 years (2021 to 2025), Relmada Therapeutics, Inc.'s net investment gains (losses) has grown at a -40.6% compound annual growth rate (CAGR), from -$636.01K to -$79.21K.
- What does net investment gains (losses) mean?
- Net realized and unrealized gains and losses on the company's investment portfolio, including equity securities, debt securities, and alternative investments.